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Altho u ~ h a few ~isp~~2ta r 2po r ts have bee~ pub lished tc 
~G nsequence this a~ti-enzy~a t i c eff ect. a~d the resultqnt 
ttoloc ic zparinr of c~t0ch0lamines , t c s been ~ncri~inated 
as partl y r e spo ~ slbl 0 f e r t he hypersansltivtty of ~yper-
actions of sympattomimetic amines. 
nather recently a cl a ss of anti-melancholy druITs, or 
:'psyc h ic e nere; izers", have been maCie clinically available. 
These agents seem to act a s anti-depressants by virtue of 
their mono amine oxidase antagonizing properti.1:0 s . 
It was strange, therefore, to note in the literature 
that a clinical psychotherapeutic incompatibility existed 
between concurrent thy .ro i d and monoami ne oxi c! ase in~ U_; i tor 
medication. Peculiar changes in thyroia function, bloo d 
pressure, and blood g lucose levels were also noto~ cl1.nically 
with the latter med!caments. The present research was 
unr1ertaken, uslng bloo rl :::i: 1.ucose. blood pressure. and acute 
and subacute toxicj.ty studies as parameters. to evaluate 
:t v 
thesa paradoxical reports. Male, albino rats were employed 
as sutjects. 
Two che:dcally diss1.milar, irreversibly actin~, monoamine 
oxidase inhibitors, ip2on iazid (11ars i lid) and M0-911, were 
selected as test compounds. 'l1he de. i ly intra.per i tonea.l 
injection of iproniazid (175 mg/kg) and M0-911 (10 and 25 
mg/kg) for a three week period elicited only inconsequent';.al 
blood sugar changes in both cuthyroid and hyperthyroid animals. 
Systolic pressures became si~nif icantly elevated upon continued 
injection of either dru3, and the presser effects were enhanced 
by feeding a 2 i thyroid diet. 
Limitej dopamine excretion stud 1.es i.n hyperthyroid rats 
revealad no particular changes, whereas massive. daily doses 
of ipronlazi'.1 provol.ced ir~crea2.ed excretion of the catecl-:.o lamine 
approximately 200 to 300 ]~ after fifteen days of enzyme 
inhibitor treatment. These urinary results did not parall0l 
the hypertensive effects. 
Weight loss, sluggishness, and gross and microacoplc 
evidence of vital organ damage occurred with massive, daily 
doses of iproniazid. The acute lethal effects of M0-911 were 
augmented by thyroid feeding. 
These results seem to suggest strongly that the direct 
and indirect pharmacologic actions of iproniazid and M0-911, 
given in hlgh daily doses to l"ats, are age;ravated by a hyper-
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Accumulating evidence seems to indicate that the feeding 
of thyroid extract, or the parenteral administration of 
thyroxine, produces a decline in the monoamine oxidase 
activity of various animals. This anti-enzymatic effect may 
result in a biological sparing of catecholamines which 
might be partly responsible for the hypersensitivity of 
hyperthyroid animals and isolated tissues to the pharmacologic 
actions of sympathomimetio amines. It has been shown that 
monoamine oxidase is intimately involved in catecholamine 
metabolism and that its inhibition can alter the circulating 
levels of various pressor and glycogenolyt1c amines. 
Recently a class or anti-melancholy drugs or "payohio 
' 
energizers" has been introduced for clinical use. These 
. 
compounds appear to act as anti-depressants by virtue of 
their ability to irreversibly inhibit monoamine oxi4ase 
activity. The clinical use or these substances ~•e known 
to cause a noticeable elevation in the mood of depressed 
subjects. 
Other recent evidence has been presented in the literature 
which indicates that a clinical psyohotherapeutic incompat-
ibility exists with the concurrent thyroid and anti-melanohol7 
monoamine oxidase inhibitor medication. Peculiar changes 
5 
in thyroid function, blood pressure and blood glucose levels 
such as orthostatic hypotension and hypoglycemia were also 
noted clinically with mf!.Q.Yof the latter medicaments. 
Such evidence indicates that a close relationship exists 
between the ~ !..!.!2, activity of the thyroid hornione s.nd ot 
the enzyme monoan1ino oxidaae, and that when the activitfe8for 
these substances are simultaneously altered a variety of 
peculiar effects a1u elicited. 
The p~esent research was undertaken to evaluate some of 
the possible effects of concurrent administration ot both 
desiccated thyroid and monoamine oxidase inhibitors in 
laboratory rodents. Blood glucose, blood proesure, and 
acute and aubaoute toxicity studies were employed as 
parameter1. 
~~ lement r-:.1 io >lne i · H. J <;ff i c ia l ly in t r o ,~ uced into med :l.c l ne 
believed that the Chlne es, many centuries before the birth 
of Ct r "ist, ~· ,,;,:i leePne~l t-t"' nt certatn S'.J tstar.ces, presently 
!tnov-m to cont.a.in iod lne. 8 ~\ SI' t c: .J bene.t ic ia l effects tn tbis 
iodine in the m::nr:mal.iar: :-Jody was fourd. in the tl::;rrotd e:l. nnd 9 
aud that it was firmly bound to a colloidal p!"'(>t.i::in-- lL::e 
material. Oswald later identified this as a pro t0in aari 
named it thyroglobuli.n. By hyrh:•olysts 'f th Ls c' •.:'; :::~an c~e 
r.~,,_ . .,,.,al"l l·· 1o 15'a 1-- c) 0 1·.._, ~t<'°' ·,::i ~ '"" "11 q11a...,·t·'Lt.T "'" ,,;·· L. ~- .i,_ 1 _ , u , u v a L • ,, ). ,_ '· " c<. • _ • ., . • , .•• ~- ,.,, • •• i a 
crystalline, io Jinated mat erial whic~ ~as therepe uttne lly 
a·:::tlve in hypothyroid patients; it was terrn~·5 l:t: ~yr' ::ixinr:;, 
Later Harington (1926) id en t ified thyroxine ct ~ ierlvattve 
of the amine -=teid tyrooSlne a nd assic ned to tr. e f\>t meor' tLt· 
strLH:,tural fo r rr.u1.a:; 
i.L ~•"-'-'-"-'"'!'\ 
/ . \ 
0 ~. -( \'>,~· :.:::11 
•) 
? '-· 
\ I ... 
,:: . .:.! 
Many excellent reviews snd paper3 t~v~ recent1y been 
t.r·ansport and distributton of this bcrmone (Gross and 
P~tt Ri"1r~r~ ia~~. Tn·~~~r 
- ..L ._, ......_ . • . tj '\,,> ' -. _, ..... 1.,) , :.. .Lb\.) a. ' 1 ?60) 0 Significant advances have 
a15G been made in the chemistry and physiology of the thyro td 
stimulating hormone (TSH) (White, 1946; Albert, lq4g; Rawson, 
19~G; Harris and Woods, 1947; Nelson and Bradley, 1960; 
Sonenberg and Money, 1960; Car~ten end Wynston 1 1960), and 
in tho desc1"iptton of the rol(:: thenervcu ~ system. plays 1n 
l9S7j Greer et Unfortunatelyf the mechanism of 
action of thyroxine and its analo?ues has not yet been clearly 
definedo Blood borne thyroxine can be converted to 
triiodothyronine ( TRIT) in the thyro idectomtzed rat (Gross 
and Leblond, 1951) and human (Pitt-Rivers!! aL, 1955), 
and there ts some evidence to indicate that thts conversion 
may be an essential step in forming the ''active" hormone 
(Lardy et aL, 1957). A number of' compounds have been 
implicated as the peripherally acting hormone. TRIT is 
wlthout question, at least in mammals, the more rapid 
acting (Barker, 1956,1957), and with chronic dosage, the 
more potent (Gross and Pitt=Rivers, 1954; Roche and Michel 1 
1955). Several acetyl derivatives of thyroxine, viz", 
tetraiodothyroacetic acid (T3TRAC) anrl triiodoacetic acid 
(TRIAC) have recently been isolated, they are less active 
biologically than thyroxine or TRIT (Trotter, 1955~ Goolden, 
8 
1956). However, the actual chem:ioal entity responsible for 
the observed hormonal effects still remains controversial. 
It is thought that thyroid analoBues may act directly 
or indirectly on the enzymatic activity of nervous tissue as 
they do on somatic tissues. This is significa~t as many facets 
of brain chemistry and metabolism are now being extensively 
studied. Recent investigators have outlined the possible 
metabolic pathways for the synthesis of dopamine, epinephrine 
{E), and nnorQinephrine (NE), catecholamines which a.re found 
extensively in nervous tissue. It is notewort~y in this 
respect that 1-tyrosine is the amino Heid precursor of' thyroxine 
as well as of the catecholamines (Blaschko, 1959). 
In order to underst~~d the manifold enzymatic effects 
of the thyroid hormone, investigators have delved into the 
cellular metabolism of the hormone itself. Such studies 
have shown that there are three possible pathways for the 
metabolism of the iodothyronines: dehalogenation, oxidation 
o:f the alanine chain, and esterifica.tion or the phenolic 
group (Lissitzky and Bouchilloux, 1957; Roche and Michel, 
1960). It is also believed that the iodothyronines are 
oxidatively deaminated to give a keto acid which is 
subsequently decarboxylated to give the corresponding acetic 
acid derivatives (Roche et alo, 1957; Tomita et alo, 1957)0 
In vitro studies have shown these derivatives to be present 
in skeletal muscle as well as in the liver and kidneye 
These findings apparently demonstrate that the oxidative 
degradation of thyroxine is possible in all tissues (Albright 
are regulated by the effect of todothy~onines on cytochrome 
c. Employing rat liver ho~ovenates Tipton and Nixon (1S46) 
have -J0monstrated that cytochro""!e oxidase activity is decreased 
following administration of TSE, desiccated thyroid, or 
th~rroxine" How aver, o th or workers have been unable to dupl ica.te 
theso results (Smith and Willtams-Ashroan, l0hg). It ts 
difficult to s~8W th~t thyro~1nc has a specificity of action 
on cytochrome G since adrena.1i::ctomy, lUce \;t1yro1.dectomy, tdll 
produce e fall in total body nytocbrome C (Crabkln, 1950b). 
Cytoc~rome oxidase has also teeh shown to oxtd."e 
More recently the hypothesis has been presentej that the 
a specific oxidative phc1sphorylati1~;n thus a 1101-:in<c: +:he 
{Lardy and Maley. 1954). 3nd thts may account for the hiaher 
basal metabolic rate and ecreased work efficiency of 
hyperthyroid animals (Lar·.:;y, 1957). Indeed, it has been 
found that thyroxine in v-'ttro ;~cpr·e::· ses the ratio of esterifted; 
ioeu high energyy phosphoru2 Lo oxygen (Leblond a.nd Grad, 
1948' Niemeyer~ a.lo~ 1951; Martius and Hess, 1951.,1952; 
Hoch and Lipmann 9 1953)0 Diiodothyronine and iodine. but 
n)t iodide, have a similar action (Klemperer, 1Q51). 
A number of additional facts support this oxidative 
10 
phosphorylation hypothesi so Of si gnific ance is the recent 
observation that mitochondrial swelling and contraction 
cycles are induced by thyroxine (Tapley et alo, 1955)0 
. ~ 
Evidence indicates that the mitochondrial swelling requires 
electron transport and this effect is promotad by thyroxine 
as well as by phosphate, calcium ions, and reduced glutathione, 
whereas contraction occurs in the presence of adenosine 
triphosphate (Lebninger, 1960). This becomes important in the 
light of the fact that there is a decreased oxygen consumption 
in enlarged mitochondria, which is in turn attributed to a 
decrease in adenosine triphosphate levels {Aebi, 1952). 
However, a great deal of opposition has arisen to the 
oxidative phosphorylation hYPothesis since the thyroxine 
concentration to produce these effects !!!, vitro is several 
orders of magnitude greater than that normally present in 
!!!.2.• In addition, !Q. vitro responses have not been consistent 
and sufficiently reproducible (Rawson and Sonenberg, 1959). 
Thyroid hormone exerts a significant action on the 
mammalian nervous system. The ne1~vous instability of patients 
with Graves' disease (exophthalmic goiter) has been noted 
since the disease was first recognized (Grave, 1835; Parry, 
1835; von Basedow, 1840). Similarily, the apathy and 
sluggishness of cretins has been known for centuries 
(Major, 1939). Furthermore, various psychoses have been 
associated with both hyperthyroidism and myxedema (Dunlap 
and Moersch, 1935; Jamieson and Wall, 1936). Voluntary 
muscle reflex~s are diminished in thyroidectomized animals 
11 
(Brody, 194la,b), and electroencephalogramg of athyreotic 
patients show diminished voltage, slow frequencyj and an 
absence of cortical alpha wavesu In hyperthyroid patients 
the alpha rhythm is increased (Bertrand et al., 1938). 
Some correlation has been found between the basal metabolic 
rate and the rate of alpha wave emanation from the nervous 
system (Ross ahd Schwab, 1939). In contrast to the effects 
on general metabolism, most investigators have been unable to 
detect a change produced by thyroxine in the ~ate of oxy~en 
consumption of brain slices (Harington, 1944) j n l tbo• ._.h it 
is felt that alpha wave frequency measurements during 
artificially induced hyperthyroidism are indirect meRsures 
of carbohydrate metabolism in the brain (Rubin~!!.!·' 1937). 
Bowman (1925) and Hoskins (1946) found lowered basal metabolic 
r~tes tn a large number of schizophrenic patients. They also 
described unusually htgh clinical tolerance to the effects 
of dried thyroide Brody and Man (1950), however, have 
reported normal serum protein-bound iodine levels in similar 
patients while Cranswick (1955) has described abnormally 
elevated thyroid uptakes of I131 tn a majority of schizophrenic 
patients. The administration of TR.IT to various psycho-
pathologically affected, but euthyroid, patients evokes the 
appearance of formerly latent or absent hostile emotions and 
sexual unrest (Flach~!.!,., 1960). Significant emotional 
changes, however, were not always observed (Flach!,! al., 1958). 
Paralleling the advances in thyroid research, stimulated 
by the introduction of radioactive iodine, has been the progress 
12 
which has been made in neurochemistry as a consequence of the 
introduction of iproniazid, a "psychic energizer". This 
hydrazine derivative i.1as crir:lnally syntbssized by Roche 
Laboratories for LLB chemotherapy of tuberculosis. It was 
soon evident, however, that the greatest value of the drug 
lay in its ability to create a sustained feeling of "well-
being" in psychieallydepressed patients (Crane, 1956). 
3elikoff and others (1953) attributed thi.s effect to central 
stimulation. Zeller~ al. (1952a) discovered that iproniazid 
was a potent inhibitor of the intra.cellular enzyme monoamine 
oxidase (¥.cA.O), an enzyme incriminated in the mode of action 
of certain anti-depressant drugs. 
MAO has been found in significant amounts in liver, 
kidney, and other organs and tissues (Richter and Tingey, 
1939), and is present chiefly in mitochondrial and microsomal 
cell fractions (Cotzias and Dole, 1951; Hawkins, 1952). 
Enzymatic studies have shown that iproniazid irreversibly 
blocks .MAO activity in the autonomic nervous system, brain, 
liver, and kidney, both ,,!!! vitro and in vivo (Zeller and 
Barsky, 1952; Zeller~ al., 1952b). 
The psychiatric value of iproniazid and other MAO 
inhibitors has been clearly demonstrated and has led to the 
introduction of a large number of chemically hetero~enous 
anti-depressants (Delay and Buisson, 1958; Geyer, 1958; 
Tobin et al., 1959). Evidence indicates that MAO is important 
in the metabolism of serotonin (5-HT) and the catecholamines, 
and that the anti-depressant effects elicited by the MAO 
inhibitors are related to the central nervous system changes 
in these monoamines (Pletcher, 19579 Udenfr1end et al., 1957; 
Spector et alo, 1958) o The relation of HAO to catecholamine 
metabolism was first recognized by Blaschke et al. (1937) 
who demonstrated that the enzyme oxidatively deaminated 
epinephrine. Brodie et ,!!o (1959) have shown that after 
single, large, oral doses of MAO inhibitors both S-HT and NE 
levels increase stgnificantly in dog and rabbit brain. 
However, contrary to previous reports it has been found that 
0-methylat1on probably constitutes the major pathway for the 
catabol1sm of this amine (Armstrong~ al.~ 1956; Axelrod, 
1957). MAO has also been incriminated in the metabolism of 
tyram1ne and dopamine - (Spector~.!:..!·, 1958; Resnick, 1959). 
It is known that thyroid hormone potentiates the action 
of epinephrine on oxygen consumption and basal metabolic rate 
(Lardy, 1957), and heart rate (Gravenstein and Thier, 1960). 
This potentiatlon of the activity of epinephrine on the 
resting blood pressure (Gerlei, 1938) and on isolated arteries 
(Smith, 1954) has been explained a~ the ability of thyroxine 
to elicit a fall in tissue amine oxidaae levels. Likewise, 
Burn and Marks (1935) showed that thyroidectomtzed rabbits 
were slightly less responsive to epinephrine induced 
hyperglycemia than normal animals. More recent experiments 
have shown that feeding of desiccated thyroid causes hepatic 
MAO of rabbits to diminish, whereas thyro1dectomy causes MAO 
activity to riseo The rise in blood glucose caused by 
injected epinephrine is greater in rabbits fed thyroid extract, 
1 r: th:yrc:-1 :Jactomlzed rabbit~ ha8 been e1~rlu ined by the rlse of 
<' 1'1d- '')T't l 1-. ,c;_r,- 7 ) .. LC'!", {\. ("ial'k 1 ')(0 \/ a ~- e.--, ,.., • . .~. - ~ ,_·· :_')"' ,j .,,,._ ' .-. , ,.,.; - (I 
Dub nick e t. al " ( l '1 6 O ) re po r t that r 0 nt live1" fl;~i\O act:i.vity is 
. h ., remain unc a~gs~ . 
under hyperthyroidism was shown t0 re8ch a minimum only 
after twelve days of treatnient, ·;_t:<.\'minatlon of' thyr·oi-:i 
feeding allowe.,:. MAO activity tc> retnrn to no1·mal with.in 
fourteen days, and consequently the r eversible deerease in 
MAO activity by thyroid hormone v:as con,sie!ered to be an 
indirect suppression of the enzymej perhaps through a 
regulation of synthesis of the enzyme o This supposition 
is also shared by others (Ozaki !,! al., l''t/J)" Ir; contrast 
to the work of Spinks and Burn (1052), i~ has beet shown 
that there is no correlation in MAO actJ.v ·Lty andblooc1 suP-2.r 
levels in the frog (Smith, 1960). 
The distinct psychotropic actions 01 thyroxine and 
iproniazid proves interesting when one considers the clinical 
thla r 0port ana has reported thg t a r ~r&~~xical apathy ~nd 
sluggishness supervenes in depressed patients receivln~ both 
lnhlhltor action is concerned with tbqi r respective efficacy 
~r t his dise ase, and thi s pr0~2dure ai~~r2 t hP re~ronss of t he 
salat~: y ~nti-ang5nGl cff~cts :f lpr sni azid wsre first ~epo~ted 
Cossio, F;}S9; Schwel.zer, 195~1; ?',!IasteP d 8,nd Donoso,, 1959). 
Several hypothese3 have been postul ated a3 to the mechanism 
of tbe anti~anginal effects of the Y'..ti.C, in.hiblto:r ,::: " flia::ite:r's 
and Do nc so (1959) find that 1pron l~ z1d 0auses ah elevation of 
myocarG.ia1. 5-B'r, amJ that relief from a ncina 18 mediated 
through myocardial and cerebral autonomic nerves" Ce.sarrrnn 
(1957,1959) proposes that iproniazld may influence cardiac 
rn.etaboll s m through some enzyma.t ic mechanism. Pletcher anc 
Pellmont (195fi) have demonstrated tbat a striking ris;;; :tn 
Tl'.yocardial catecholami.nes occurs in ipro r.ti8.Zi.d treated g t.c '~ea 
pigs , and they have related these changea to the the rapeutic 
effects. of this compouncL In certain hypothyroid patients, 
however, thyroid in doses as low as eight to sixteen 
16 
milligrams has produced severe anginal pain. With concomitant 
therapy with an MAO inhibitor, it was found that thyroid 
dosage could be gradually increased to relleve the myxedema 
without aggravating the cardiovascular complaint (Wolffe and 
Shubin, 1959). 
The administration of desiccated thyroid has been 
shown to elevate the cardiac output whereas myxedematous 
patients show a subnormal output (Scheinberg ~ !!·, 1950). 
Hyperthyroidism appears t~ increase the mean systolic 
ventricular pressures and the resting blood pressure of 
rabbits (Fullerton and Harrop, 1930; Spinka, 1952). In 
contrast, iproniazid regardless of its monoamine sparing 
effects, has been shown to cause severe orthostatic hypotenaion 
(Randall, 1958) possibly through ganglionic blockade (Gertner, 
1959). It has, for this reason, been suggested for the 
treatment of hypertension (Harnes, 1958). 
MATERIALS AND METHODS 
Subacute Studies 
Sixty male, albino rats of the Wistar strain, ranging 
in weight from 170-210 g, were divided into 10 groups of 6 
an1mals each (Table 1). Each group was housed separately. 
The environmental temperature was maintained between 250-2( 0 c. 
Initially, all 60 rats were placed on a control diet conslsttng 
of water ad .l!.£0 and specially repelleted tablets of Purina 
Laboratory Chow1 for 7 days. On the eighth day, groups I 
through V ~ere continued on this c~ntrol diet while groups 
VI through X were placee on a similar diet which. tn addition, 
contained 2 % powdered Thyroid UGSoPo 2 The anim91S were 
then maintained on these respective diets for an additional 
21 days. To prevent vitamin A deftctt, due to increased 
ut111zatton of this vitamin during the thyroid treatment 
(Hague et.!!·• l948) and to retard weight loss (Logaraa and 
Drummond, 1938), all animals were given 3 drops or Oleum 
Percomorphum 3 (vitamin A and D) orally every tht~d day of 
the study. On the eighth day, normal blood pressure and 
blood glucose levels were taken~ Subsequent blood pressure 
levels were recorded daily, and blood sugars were measured 
every third day. 
-
l Ralston Purina Coo, Sto Louts 2, M1ssouriv 
.. 
2 Armour Laboratories, Kankakee~ Illinois. 
3 Mead Johnson and Coo, Evansville 21, Indiana. 
17 . 
18 
Diet. The incorporation of thyroid extract into the 
diet was considered the most satisfactory method of hormone 
treatment (Anderson et alo, 1943}, although it presented 
certain technical difficulties which required the extempo-
raneous repelleting of the animal feed. The food product 
as manufactured 4 contains no excipient to bind the fibrous 
meal. Instead, moisture in the form of steam ls added 
directly to the mix, and the moistened meal is forced through 
a die under hlgh pressure. Our facilities dld not permit 
high compression tableting so that moisture alone was not 
a sutficient adhesive for the fibrous and resilient meal. 
Starch, dextrin, sucrose, glucose, lactose, or other 
alm1liar carbohydrate-like excipients commonly employed to 
prevent crumbling, were inappropriate to use as these would 
have a tendency to modify certain metabolic effects of the 
thyroid treatment. A method found simple and expeditious 
to produce an acceptable remade chow tablet, using limited 
and easily accessible equipment, was to crush the hard, 
brittle pellets by use of a Wiley laboratory mt115. passing 
the coarse material thence thl'ough a Mikro Samplmt116 
(model 579A) to give a number 60 powder or finer. To 
each 100 g of this powder was added 40 ml of a warm, 
4 Letter from Special Chows Research Division, Research 
Department, Ralston Purina (c., St. Louis 2, Missouri. 
5 Standard Model Number l, d1str1buted by A.H~ Thomas Coo, 
Philadelphia 5, Pennsylvania. 
6 Pulverizing Machinery Co., Summit, New Jersey. 
19 
freshly prepared, gelatin-acacia solution made by dissolving 
10 g of Gelatin (granular) UaSaPo and l g or Acacia (pmvder) 
UoS~Po in 100 ml of boiling ~!stilled watere The btnder 
and powders were then mixed thoroughly to form a damp mass. 
The latter was then sifted through a number 10 mesh brass 
screen to form granules. These particles were then passed 
through a number 20 mesh screen to obtain a finely ~ranulated 
mass. 
~o prepare a 2 % thyroid diet it was necessary to 
readjust the formulation so that 100 g of the mass contained 
90.76 g powdered chow, 2.00 g powdered thyroid, and 7.2l+ g 
of excip1ent. These substances were prepared and mixed as 
previously described. Using a hand driven, single punch, 
Stokes tablet machine (model A3-Eureka)7 with a 1.27 cm 
standard concave punch and d1e set for maximum fill (l.09 
cm), the damp granulation was compressed 1nto Oo5 g convex 
tablets having 2.0 mm edge thickness. The pressure on the 
punch approximated 7.5 tons per square inch. The tablets 
were allowed to dry and harden thoroughly at ambient room 
temperature (approximately 21°c) for 36 hours or longer. 
Drugs. Eight of the 10 groups of rodents received 
daily intraperitoneal injects of a MAO tnhtbttor for the 
21 days concomitant with the thyroid or control dtets. 
The remaining two groups were used as controls (cf. Table 1). 
~nimal groups I, II, VII, and VIII were injected with 
7 FoJ. Stokes Corp., Philadelphia 20, Pennsylvania. 
igonicotinyl-2~isopropylhydraz1ne phosphate (1proniazid)8, 
a hydrazide enzyme 1nh1b1tor, an gr-oups III, IV, IX, and X 
were injected with N-benzyl~N-methyl-2-propyrflaJl1ae 
hydrochloride (M0-911)9, a non-hydrazide inhibitor, in the 
doses as outlined in Table 1. The structural formulae of 
these drugs are given in Figure I-A (Appendix)o The 
solutions tor injection were prepared by dissolving the 
respective salts in isotonic saline. The pH of the solutions 
approximated 3o5. 
Methods. Indirect systolic blood pressures were determined 
by the method of Kersten et!_!. (1947) ustng a Photoelectr1c-
Tensometer10. All readings were taken to the oloseet 5 mm Hg 
and were recorded as direct instrument values. 
Blood glucose levels were determined by the colortmetr1c 
.method of Nelson ( 1944) aa modified by Somogyi ( 1945). 
Samples were read tn optical density units on a Baueoh and 
Lomb Spectrontc 20 colorimeter, type 39-24-1011, using the 
special ! inch diameter ouvette as provided by the manu-
facturerl2. To prevent reading errors, the cuvettea were 
calibrated using a standard CUS04 solution. The colorimeter 
was standardized by using known amounts of dextrose diluted 
,_ 
8 Generou~ly supplied as Marsilid by Dr. Robert E. 
Dixon, Roche Laboratories, Nutley 10, New Jersey. 
9 Generously supplied by Dr. G.M. Everett, Abbott 
Laboratories, North Chicago, Illinois. 
10 Metro Industries, Long Island Ctty 6, New York. 
11 3ausoh and Lomb Optical Co., Rochester, New York. 
12 Spectronic 20 test tubes# 33-29-27, Bausch and 
Lomb Opttcal Co., Rochester, New York. 
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to 100 ml with glass distilled water. Seven concentrations 
were employed and ran8'.ed from 60 to 210 mr /110 ml ( T·ab le I-A) . 
Five readinRS of each concentration were made by takin~ 0.1 
ml of the sample and adding it to 1.5 ml of d i s tilled water. 
To this mixture was added 0.2 ml of 5 ,.,.,, ry . ("';.o /o wnu 4 and 0.2 ml of 
0.3 N Ba(OH) 2 . All chemicals were of reagent quality. The 
suspension was centrifuged for 5 minutes at 4000 rpm's. One 
ml of the s upernatant ltquid was then pipetted into a Falin-Wu 
sugar tube which had been previously filled with 1.0 ml of 
alkaline copper tartrate solution. The mixture was heated in 
boiling water for 20 minutes and tLen cool e d in running tap 
water for 2 minutes. To the cooled solution was added 1.0 ml 
of arsenomolybdate reagent and the s olution was nixed and 
allowed to stand for approximately 2 minutes. After adjustin~ 
the vo lume of the resulting colored solution to 8.a ml with 
distilled water the solution was placed into the cuvette. A 
blank determination was prepared in the same manner usina 
0.1 ml of glass distilled water in lie u of the dextrose . The 
blank cuvette was then placed in t~e color imeter and the 
instrument adjusted to an optical density of zero and a wave 
length of 500 mu. The sugar sample was then substituted for 
the blank and the resultant optical density read . The mean 
of the 5 readings for each sample was plotted. a gainst the 
concentration (Table I-A; F igure 1). The resultant plots 
were then adjusted using the line regression metho d as 
described by Ostle (1956) and the mathematically derived 
line was plotted. 
2 
Blood samples were obtained by direct tntracardiac 
puncture with a 0.25 ml syringe and a number 27 gauge-! 
inch hypodermic needle. In order to obviate blood samplini:i: 
difficulties and possible epinephrine release (Weil, 1952), 
the samples were taken while the animals were lightly 
anesthetized with pentobarbital sodium (20 mg/kg) . To 
eliminate variances in blood glucose levels, due to 
differences 1n the food intake of the animals, all animals 
were fasted for 17 noure prior to the blood collections. 
The blood samples were processed 1n the aforementioned method 
employing a blank with 9ach group ot samples. The blood 
glucose concentration ct eaoh sample was determined from 
instrument readings and the respective concentration tn mg/100 
ml read from the line graph (Figure 1). 
~tstolostc Studies. Samples of ltver. kidney, spleen, 
and thyroid tissue were remc-11ed from one repreaentat1ve 
animal in each group studied. These tissues were fixed in 
Bo11in' s solution, dehydrated, cleared in xylol 9 mounted in 
paraffin, and sliced 1.nto 10 ll sections. The sections were 
stained with hematoxylin and eosin and examined for general 
pathology. 
Urinarz Dopamine Studies. Twenty-four hour urine 
samples from groups II , V, and X were collected in 2 N H2S04 
on the eighth and fifteenth day of the studies. The pooled 
samples were filtered and processed tor extraction of 
catecholamines (Crawford and Law, 1958). An aliquot of the 
urine extract was passed through a strongly acidic, cationic 
• 
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exchange resin (Dowex 50W-XB, Na+ form)l3 and the dopamine 
was eluted with 8.0 ml of 2 N HCl (Bertler et al., 1958). 
Urinary dopamine levels were determined by the trlhydrcxyindole 
method of Carlsson and Waldeck (1958) employing an A~tnco-Bowman 
spectrophotofluorometer14. 
Acute Toxicitz Studies 
As a consequence of the subacute MAO inhibitor and thyroid 
interaction studies, an apparent augmentation was observed in 
the mor'te.lttr of hyperthyro1c1 rats receiving high daily 
parenteral doses of the h7draztde (tpron1az1d) or the 
non-hyd~aztde (M0-911) enzyme 1nh1bttor (Table 1). To 
evaluate this possible hormonal sens1t1zat1on, 73 male rats 
{Wiatar strain) ranging in tnttlal weight from 133-190 g were 
employed in an acute mortality stud7. Four groups of fasted 
animals (172 g mean weight), 8 animals to a group, prevtously 
fed on a 7 day control diet ad lib.,15 were injected 
--
1ntraper1toneally with doses of M0-911 differing by .03 log 
units (Table 4). Four other groups (127 ~mean weight), 
previously made hyperthyroid by a 7 day desiccated thyroid 
(2%) ad l1b. d1etl6, were treated in an identical manner. Nine 
--
. 
additional hyperthyroid rats (130 g mean weight) were injected 
solely wlth normal physiological saline solution and served as 
controlso All animals were housed at a temperature of 250-27oc 
13 JoTo Baker Chemical Co., Phillipsburg, New Jersey. 
14 American Instrument Coo, Inc. Silver Spring, Maryland. 
15 Control diet was identical to that used in the subacute 
studyo 
16 Thyroid diet was identical to that used in the subacute 
study. 
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and were provided prior to MAO inhibitor medication with 
oral vitamin A and D supplementation at 3 day intervals. 
RESULTS 
SUBACUTE STUDIES: 
General Observations. The MAO tnhtbttor medicated 
antmals exhibited somewhat less motor activtty and seemed 
easier to handle than control animals. Wlthtn 3 to 4 days, 
all thyroid fed rodents showed considerable irritability. 
whereas the hyperexcitability was less apparent when thyroid 
was combined with the enzyme inhibitor me1.Hcation. The 
augmented apathy in ' he latter instances became increasingly 
pronounced with continued drug administration. 
Food and water consumption decreased with iproniazid 
therapy but was less pronounced with M0-911. Thyroid fed 
controls seemed to increase their intake twofold, while 
M0-911 and iproniazld treated, hyperthyroid animals seemed 
to be restrained in their feeding habits. The demise of 
drug treated animals was always preceded by complete cessation 
of food consumption. Mean body weights of euthyroid subjects 
under iproniazid medication fell steadily while the weights 
of animals receiving M0-911 showed either slight decreases or 
moderate increases . Weight decline also occurred in the 
hyperthyroid groups; this was 1~st marked in those animals 
also receiving a MAO inhibitor {Fi~ure 2). Untreated animals 
maintained on the control diet showed normal weight gains. 
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Sporadic incidence o f di E~:c r~1 t:: a v, as com;non to all t..bt · 
enzyne inhibitor tre n. teu rodcnt ,s nnd wa ... particularly 
prevalent in those anina ls re ee i vi nf::; ci0< i cc::-. ted t:.1yrcii do 
'I111e feces of t.lAO inhi~;i t o r• tre,s. t c:d m1i :nc,ls were cor..te d with 
considerable intestinal 1m1cus. With iproniazid therapy, 
gross observations of urine samples showed considerable 
homo i;lobin; blood specimens used for ::;lucose determinations 
contained laked erythrocytes. Reddish colored oc·u.lar 
discharges, resembling dried blood, were also regularly 
apparent with iproniazid, but they were present less frequently 
with M0-911. An abnormal dec;ree of salivation occurred with 
both iproniazid and L0-911 treat;:;rnnts in the euthyroid and 
hypertbyroi d animals, but it appeared i;,ore prevalent in those 
individuals treated with the latter compoillldu 
Subacute Toxicity. Symptoms of' iproniazid toxicity 
rapidly developedo A muz1ber of e n thyroid rodents given the 
250 mt/kg dose of iproniazid died on the second day of 
injection and all died within 8 days (Table 1); concur>rent 
aclJninistration of thyroid to a similar croup produced 
expiration within the 21 clay study period whereas concolni tant 
thyroid feeding and iproniazid treatment resulted in all 
deaths within 6 dn:rs o Al though no deaths followed thyroid 
feeding (group V), or K0-911 administration (groups III and IV) j 
a combination of these substances caused all animals to die 
within 15 days (groups VIII and IX). 
Tissue Pathologyu Livers removed from 21 day, iproniazid 
treated animals displayed small lesions; kidneys appeared dark 
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r d whtl spleens of all the subjects 1 almost black. 
Histologic examination of these or ans aled hepatocellular 
damage, onal tubule necrosis, and con able erythrocyte 
fragmentation 1n the spleen. Rodents sacrificed after 21 
days of M0-911 medication exhibited none of these organic 
changes, although several of the spleens appeared dark red 
in coloro Thyroid and M0-911 tissues were unable to te 
procuredo 
o"~t:l1c Blood Pressure and Blood Glucose. Blood preasure 
and blood glucose determ1nat1ons are plotted in Figures 3 to 
8. Standard deviations were derived trom t , a formulae: 
• J 
where Y represents the individual reading, Y the sample mean, 
n the sample number, s2 the variance, and a the standard 
deviation with n-1 degrees of freedom (Ostle, 1958). A 
t-distr1but1on formula { ~ = Y! t ~-r- ) was applted to 
the normal mean blood pressure and glucose levels of the 
sixty samples employed using a t value of 2.660 (Dixon and 
Maeseyt 1957). u represents the mean value plus or minus 
the resultant devtat1on within 99 % confidence limits with 
59 degrees of freedom. The calculated normal, mean blood 
pressure and glucose levels were determined as 110 ! 2.65 
mm Hg and 104 ± 3.87 mg % respectively. The standard 
blood pressure deviation of the 60 samples was calculated 
to be± 7.66 mm Hg and is represented in the figures by the 
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solid, horizontal lines. The glucose mean standard deviation 
was calculated t.o be + 11.20 mg % and is represented by the 
dashed 11nes~ All readings, inclusive of the greater 
percentage of their individual standard deviations, when 
present outside of these areas, are noted as statistically 
significant changes. 
Three week da1ly treatment with either enzyme 1nhib1tor 
and/or desiccated thyroid el1e1ted no significant changes in 
blood glucose levele, and only tn those animals near death-did 
the conoentrat1ons fall (Figures 3 to 8). 
Blood pressures were elevated by both thyroid and "MAO 
tnhtbttor treatments. Elevattons in mean arterial pressure 
were witne~sed with thyroid after 48 hours of feeding, rose 
to peak levels by the sixteenth day. with a plateau occurring 
at approximately 157 mm Hg. Blood preesures 'f eutbyro1d 
subject3 after 48 hours ot 1p~on1az1d (175 mg/kg) med1oat1on 
produced s1gn1f1cant elevattons, followed by a sharp increase 
to a peak reading or about 16$ mm Hg within 5 days. Preesures 
remained stable until the eighth day when they fell precipi-
tously below normal; readjustment to normal values occurred 
by the thirteenth day (Ftgure 4) even with continued d~ily 
med 1oat1on. 
A similar blood pressure pattern was exhibited in M0-911 
treated euthyroid rats. In contrast to 1pron1az1d, M0-911 
treatment produced an initial transient hypoteneive effect 
lasting 3 to 4 days. This hypotens1ve pattern appeared 
similar at both dose levels, but was of shorter duration at 
2 ') 
the 10 mg/ke; dose. ~lfitbin 7 to B days of daily l10~911 
treatment blood pressur•es of both d c: s s d "Toups rose to 
approximately 155 mm Hg. This marked hypertensive stnte, 
as wlth iproniazid treated subjects, persisted for several 
days. The post-hypertensive pressures with M0-911, however, 
did not fall below normotensive levels but stabilized slightly 
above the mean normal pressures (Pigm:'es 5 and 6). 
Treatment of hyperthyroid animals (3 day thyroid feeding) 
with M0-911 produced a marked hypertensive response after 2 
days of drug adMinistration, with higher peak systolic 
pre ,ssures preva1l1ngtha.n durinc enzyme lnhibi tor or· thyroid 
administration alone (Figures 7 and 8). Blood pressure 
levels fel~ erratically after the eleventh day of treatment, 
and all animals expired either on the fourteenth or fifteenth 
day. 
Ur·inary Analyses. Urinary dopamine values appeared to 
be within normal values in rodents made hyperthyroid by the 
21 day feeding of 2 ~1'o desiccated tbyr)id (Table 2). To the 
contrary, however, these values were seemingly elevated in 
hypertensive, euthyroid animals treated with daily doses of 
iproniazid (175 mg/kg). An extremely high value was observed 
at day 15 where peculiarly enough the blood pressure values 
were within normal limits (Figures 3 and 4). 
ACUTE TOXICITY STUDIES 
The acute toxicity results are presented in Table 3. 
Because a perfect statistical analysis of the respective 
LD5o's was not possible, due to t he limited number of animals 
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employed and the one group aberrantly r(zponatng to M0-911 
at 175 mg/kg, only an approxi~ation to this dose for the enzyn:e 
inhibitor in the euthyroid animals could be made; this value 
was found to be 183.5 ~ 15eO {SoE.) mg/kg by using a graphic 
method or analysts (De Beer, 1945). It should be noted that 
in the thyrotd-M0-911 treated group all deaths, save one at 
the 152.4 mg/kg level, occurred within 2 hours. These results 
show rather conclusively that the 1ntraperitoneal toxicity of 
·M0-911 in hyperthyroid rats ie markedly increased and that the 




Results of subacute toxicity experiments 
with iproniaztd and M0-911 administered daily 
~---·- '111-
Group D~se of MAO Diet Deaths 
Inhibitor 
..... ___ --
I Iproniazid Control All in 8 
2.50 mg/kg days 
II Ipron1az1d Control 2 in 21 
175 mg/kg days 




v None 2 % None 
.. 
Thyroid 
VI Iproniazid 2 % All in 2 250 mg/kg Thyroid days 
VII Iprontazid 2 % All in 6 175 mg/kg Thyroid days 
VIII MD-911 2 % All in 14 I· ~5 mg/kg Thyroid days I I 
I 
IX MO-gll 2 % All in 15 l 10 mg/kg Thyroid days 









Urinary dopamine levels of iproniazid 
and thyroid treated albino rats 
,-
I Day of ' Urinary Dopamine 
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15 475 112 ± 7.9 




15' 2159 116 + 27.0 
-
B 482 140 ± 9.0 
Thyroid (2%) 
Fed 



















Acute toxicity of intraperitoneally 
administered M0-911 
Initial 






M. T ean I 
Weight Dose 
1




! % Deadl 
t 
' Inject1on1 
t -~+--+--- I 
I i l 
I 185 i 187 .5 4/8 $0 .0 !' 
180 II 175 .o 2/8 25 .o 
163 163.0 3/8 37.5 
161 152.4 2/8 25.0 l 


































* All deaths within 2 hr of dosing. 
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Ftg. l. Blood glucose standard1zat1on curve. 
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Fig~ 2. Graph of mean body wetght e anges oL rats under MAO end/or thyrold medication. 
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DISCUSSION OF RESULTS 
The ostensible reduction of motor activity observed 
in the MAO inhibitor medicated rodents, at first glance, 
appears contradictory to the clinical evidence indicating 
that these compounds are effective psychomotor stimulants 
(Loomer~ al., 1957; Tobin~!.!,., 1959; Voelkel, 1959}. 
One must consider, however, the ability of these inhibitors 
to reduce the duration of sleep (Kline, 1958} and produce 
insomnia and weakness (Ayd, 1959; Hawkins~!!·• 1959; 
Tobin !t !!J..o, 1959). Employment of high, subacute doses can 
thus produce a rapid and profound elevation of central 
nervous system activity causing generalized body fatigue; a 
fatigue condition which would effectively mask its cause. 
In the animals where thyroid was combtn~d with enzyme 
inhibitor medication, fatigue and weakness were undoubtedly 
reflections of apathy. This ts a plausible conclusion since 
hyperthyroidism itself ts capable of producing tncreased 
central nervous system activity characterized by nervousness 
and hyperexcttab111ty (Rawson, 1959). Although Dongier ~ !.~·, 
(1956) indicate that . there 1s no correlation between the 
degree or anxiety and the rate of thyroid secretion, James 
(1941) 1e or the opinion that the level of thyroid activity 
does a great deal to determine the relative excitability 
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of all nervous processeso_ Again 9 such gross psychomotor 
stimulation, incurred through hyperthyroidism, often produces 
fatigue and general weakness (Rawson, 1959). Wang (1927) has 
actually demonstrated a depression of spontaneous activity 
in rats after two weeks oral medication with desiccated thyroid 
which has been attributed to increased fatigue of these animals$ 
An apparent corollary then is that the increased apathy 
observed in hyperthyroid rodents medicated with MAO inhibitors 
may be a result of continuous, immense, potentiated central 
excitability which brings about a rapid generalized fatigue. 
Whether or not this potentiated fatigue occurs through a 
combined effect of thyroid and MAO inhibitors upor.. amine 
oxidase systems is an intriguing question. 
The apparent increa.se in food and v1ater intake of thyroid 
fed rats, irr espective of their continued weight lossj agrees 
well with the reports of Carlson {1941) and Barker (1951) 
but not completely with that of Richter {1933). No doubt the 
use of vitamins A and D as dietary supplementsoffset, to a 
degree, certain of the adverse effects of high doses of the 
thyroid substance. Interestingly, vitamin A has been reported 
to protect animals against the rise in oxygen consumption 
caused by desiccated thyroid (Sadu and Brody, 1947). 
The weight gains ex:perienced with M0-911 medicated 
animals correlates well with clinical observations that N.AO 
inhibitors produce increased appetites resulting in significant 
weight increases (Tobin et alo, 1959)0 On the other hand, 
the !eouliar weight loss observed with iproniazid may be a 
result of the induced toxic!ty ca.used by the htgh subacute 
doses employed (250 and 175 mg/kg). The combination treatment 
with thyroid and inhtbttor 1 which caused both a drastic weight 
reduction and loss of appettte, is difficult to interpret, 
but tt certainly testifies to a potentiat1on of toxicity. 
Toxic manifestations of 1prontaz1d tn euthyroid rodents 
were clearly evident as deaths occurred tn both the 175 and 
250 mg/kg dose levels during the 21 day study, Amonr. these 
animals a s1gn1!'1eant erythrocyte dastr1iction was observea. 
Thie is not surprising in as much as hydrazine and its 
analogues are known to possess hemolytic properties. Benson 
et al. (1952) have shown that short term iprontazid 
- -
administration causes increased destruction and formation 
er1throo7tes. Moreover, histological 1nvest1gat1one of 
animals treated with high doses or hydr~z1de 1nh1b1tore often 
reveal increased erythrocytosis as evidenced by hepatic, 
renal, and spleld;o hemos!derosis, profuse bone mar~ow 
oellularity, and hyperemia of the spleen ( b1nden and Studer, 
1959). The lack of gross hemolytic change .· bserved wt th 
M0-911 offers added evidence tha.t sueb toxicological syndromes 
are most ltkely the result of the hydrazine moiety of 
hydrazide MAO inhibitors. 
A singular toxioologtcal observation was the apparent 
reddish, ocular discharges whioh occurred with subacute 
medication with both .iproniazid and M0-911. This effect has 
a parallel ic the report (Gray, 1961) that ocular di s charge 
of a porphyrin-like material occurs in rat s under subacute 
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medication with etryptamine, a new indole MAO inhibitor. 
The feces of ¥.AO inhibitor treated rats were often 
coated with considerable mucus. This observation parallels 
the gastrointestinal hypermucosity noted with the psychiatric 
use of similar psychic energizers (Sainz, 1959); this side 
effect may reflect irritation of the alimentary canal induced 
by the medication. 
In order to evaluate the possible blood glucose responses 
of MAO inhibitors in euthyroid and hyperthyroid rodents, it 
became necessary to demonstrate the possible effect of both 
a hydrazlde and a noohydrazide inhibitor on blood sugar levels, 
particularly since Underhill (1911) has stated that subcutaneous 
injection of hydrazine sulphate into dogs produces a fall in 
blood glucose wtthin 24 hours. Also, Underhill (1911, 1914) 
reports that this compound when administered to dogs depletes 
both liver and skeletal glycogen and prevents glycosuria of 
depancreatized animals through inhibition of sugar excretion 
by the kidney. These observations tend to indicate that the 
hypoglycemic effect seen clinically with iproniazid medication 
(OVConnor et al., 1953; Alexander and Berkeley, 1959; Greenblatt 
and Kahn, 1959; Weiss!.,!!.!·' 1959) could be in part the 
H H 
contribution of the hydrazide moiety (-N-N-) in this compound. 
Surprisingly, however, subacute administration of iproniazld 
and M0-911 to both euthyroid and hyperthyroid rodents evoked 
no significant blood glucose changes. 
Of further interest was the lack of significant blood 
glucose changes resulting from 2 % desiccated thyroid feeding. 
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treated rodents. 
Although extensive investigation tends to support the 
hypothesis that iproniaztd ia not a practical ,!!! ~ 
potenttator of the effects of peripheral E and NE (Cahan 
~ !..!:.·, 1953; Schayer and Smiley, 1953; Schayer~_!!., 1953; 
Balzer and Holtz, 1956; Kamijo !?,! !!,., 1956; Corne and 
Graham, 1957; and others), evidence indicates that breakdown 
ot E and NE is depressed in iproniazid treated rats (Schayer, 
1953; Schayer et al., lq55)§ The resultant peripheral 
--
vaaopressor effeote of these hormones may, in part, explain 
the h'YJ)ertension. Goldberg (1959) has reported that 
phenlpre.zine, a chemical analogue or 1prontazid. ca1Jses a 
marked pressor effect in anesthetized, vagotom1zed dogs when 
given intravenously~ 
Rodents fed 2% iesiocated thyroid presented no such 
1noons1stent vascular effects; the hypertension developed 
rapidl7 and was maintained. This confirms the findtngs ot 
Sami7 (1952) with th119oxine tn rats and rabbtts. Although 
hypertension ts not a normally reported syndrome in hyper-
thyro1d1sm, Blumgart et al.(1930) have stated that blood 
--
volume increases in this condition. This together with a 
probable increase 1n cardiac output can elevate blood pressures 
during thyroid overactivity. Although 1t is simple to accept 
the supposition that elevated cardiac output is primarily a 
function of increased metabolism, Rasmussen (1941) declares 
that induced hyperthrroidism results in cardiac changes that 
cannot be directlr correlated with metabolic rate. In addition, 
49 
Leblond and Hoff (1944) indicate a possible direct effect of 
thyroid on the heart. Whether these effects are directly 
responsible for elevated blood pressures ls difficult to 
ascertairiu A noteworthy observation is the fact that when 
thyroid and inhibitor administration are combined in rodents 
all hypotens1ve reactions as exhibited with MAO inhibitor 
treatment alone are obliterated. Whether such responses are 
a direct potent1at1on ot combined tnhtbttor and thyroid 
treatment requires further 1nvest1gatton. 
Stnoe MAO tnhibttors are capable or inhibittng a normal 
oatabol1c pathway or dopamine in vivo (Holtz, 1959~, one 
--
would expect an increase of this substance in oertatn body 
tissues. After prolonged 1nhtbttor treatment in rodents 
(14 days) with high, 1ntraperttoneal doses of tproniazid, 
a significant rise 1n ur 1ne.ry dopamine level a did 00011r. 
Dopamine acts as a pressor in the rat (Vogt, 19$9), although 
it ts decidedly less potent than other cateoholaminea 
(Pennefather and Rand, 1960). Samty (1952) noted that 
hyperth7%'o1dism in rats augmented the presaor response to 
intravenous doses of d1hydroxyphenylalanine, the precursor 
or dopamine; hts results inferred that this effect was due 
to enhanced receptor senstt1vity to the formed dopamine. 
Although it was not possible to determine urinary levels of 
dopamine from MAO inhibitor treated, hyperthyroid rats 1n the 
present experiments, tt might very well be that Se.miy's 
findings explain, in part, the rapid onset and marked presser 
effects recorded tn these treated animals. It ts dtffioult, 
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on the other hand, to explain the apparent lack of correlation 
between high urinary dopamine levels and the pressor responses 
in response to high daily doses of iproniazido It may simply 
be a case of cardiovascular adaptation of the drug treated 
animalo 
The original intention was to administer both ipron1az1d 
and M0-911 to both hyper- and euthyroid rats in eqaimolar 
concentrations per kilogram or body weight. Since we 
originally employed iproniazid at 250 and 175 mg/kg dose 
levels, this necessitated the use or equtmolar M0-911 
concentrations at 175 and 123 mg/kg. In our preliminary 
observations, the subaoute administration of M0-911 at these 
doses produced total mortality after the second injection. 
Subsequent information received from Abbott Laborator1es17 
indicated that subaoute intravenous administration of 25 
and 10 mg/kg or M0-911 was well tolerated in rats. Therefore, 
these new doses were utilized and found to be satisfactory. 
Of significant interest was the acute and subaoute 
potent1ation or MAO inhibitor toxicity in hyperthyroid animals. 
The administration of desiccated thyroid or thyroxine is known 
to modify the susceptibility of animals to the poisonous 
effects of a number of substances. Thyroid hormone increases 
the toxicity of alloxan (Houssay and Sara, 1945), cocaine 
(Glaubach and Pick, 1931), morphine (Hunt and Seidell, 1910), 
dinitrophenol (Glaubach and Pick, 1934), epinephrine 
17 Letter from Dr. G.M. Everett, Abbott Laboratories, 
Chicago, Illinois. 
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(Kroneberg and Huter, 1951; Kroneberg, 1952)j and other 
substances. Large doses of thyroid substance may produce 
liver damage (Barker, 1951), and this finds parallel in the 
ability of certain MAO tnhibitors to intensify liver damage 
caused by certain hepatotox1o agents (Zbinden and Studer, 1959). 
However, the cause of the augmented lethality with 1proniazid 
and M0-911 is 1ot easily understood. but because of the early 
onset of malaise and rapid demtse a direct sensitivity to the 
toxic effects to the MAO 1nh1b1tor molecnle per se seems 
to be the most likely explanation. These effects, on the 
other hand. may possibly be related to ~.i.AO 1nh1bit1on coupled 
with the similar enz1'fllatic in vivo effects or thyroid 
--
feeding (Spinks and Burn, 1952; Zile and Lardy, 1959) 
resulting in an acute liberation of unbound catecholamines, 
a diminished ability of the animal to oope with stress, and 
a predisposition to fatal thyrotox1cos1s. The reported 
psyohothe~apeutic 1noompat1b111t7 of concurrent MAO 1nh1bitor 
and thyroid medication (Ba1le1 et al., 1959; Kline, 1961) 
--
may possibly be explained by this hormone induced sensttivtty 
to drug toxicity. 
SUMMARY AND CONCLUSIONS 
l. The p~esent research was undertaken u91ng blood glucose, 
blood pressure, and the acute and subaoute toxicity 
studies in rodents as parameters, to evaluate the 
possible psychotherapeutic ineompattbility which bas 
been reported to extst with concu rent thyroid and 
~IAO inhibitor medication. 
2. Datly intraperttoneal lnjactlon of 1pronlaztd or M0-911 
for three weeks reduced the spontaneous motor aotiv1ty of 
male albino rats. Concomitant feeding or two perc~nt 
desiccated thrro1d augmented this apathr. 
3. The subacute, tntraperttoneal administration or either 
1pron1aztd or M0-911 in high doses cause~ sever loss of 
body weight; thls weight 1•· es was aggrave.t a bf 
concurrent thrrotd feeding. 
4. The sluggishness, aggravated ~etght decltne. and symptoms 
ot malaise from combined thyroid and MAO tnh1.b1.tor 
medication may be e~pla1ned by an increased sensitivity 
or hyperthyroid rats to e.cut'e or subacute MAO inhibitor 
toxicity. 
5. Limited grose and h1stolog1o observations revealed that 
high, dally doses of 1pron1az1d, for three weeks, caused 
hepatic and r9nal damage and erythrocyte hemolysts in 
52 
the spleen o M0-91 l ir 11 , parent~ra l d ,ige:s of ten 
or twenty-f1.ve mill tgrams per 'k:tlol!ram did ni.:it p!'oduce 
any apparent organic cban -, o, although ~plenic darkening 
was noted o 
6. In the doses employed, the MAO 1nh1b1tors alone or with 
thyroid treatment, failed to elicit any s1gn1f1osnt 
changes 1n blood sugar. Fead1ng of a two percent th)Toid 
diet tor three weeks likewise failed to mod1t1 the blood 
glucose picture. 
7. '11he systolic blood pressures ot' 1p:ron 1e z 1.d treat d, euth 't~o id 
animals rose significantly above normotenslve levels, 
beginning arter forty-eight hours of medication. to a 
peak on the eighth day; whereupon they suddenly and 
precipitously fell to hypotenstv.e levels. 
8. M0-911, in daily doses of ten or twenty-ftve mtlllgrams 
per kilogram body weight, elicited an initial and marked 
fall in blood presauree This response soon gave way in 
both instances to a slowly developing hypertenston which 
persisted until the tenth or sixteenth day ot treatment~ 
9o The feeding of thyroid substance to H0-911 treated rats 
obliterated the 1ntt1al hypotensto and effected a sharp 
pressor response within three daJe f continued inhibitor 
medication. These pressor effects were greater and more 
acute in onset than those noted with either M0-911 or 
thyroid administration. 
lOo Urinary dopamine le~els following nA or two week treatment 





three f'oldo The urinary levels of' this biogeni c 
catecholamine could not be correlated with pressor 
responseso 
Although admittedly limited in extent$ studies of urinary 
dopamine levels did not reveal any increase after three 
week f'eeding of rats with two percent desiccated thyroid .. 
These results suggest strongly that the direct and 
indirect pharmacologic actions of iproniazid and 
M0-911» given in high daily doses to rats, are aggravated 
by a hyperthyroid state; these experimental findings 
have obvious clinical significance~ 
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FIG. I-A. Graphic configurations or the MAO inhibitors 
employed in the study. 
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It is well-established that the calorigenic, metabolic, and hemodyna.mic 
effects of norepinephrine and epinephrine are diminished or lacking in 
hypothyroid animals (Sawyer and Brown, 1935; Re.ab, ,1945; Bre'W'Ster, 1956). 
On the other hand, although there are some contraindications as to an 
enhancement of native sympathomimetic amine activity during hyperthyroidism 
(Macmillan and Rand, 1962), thyroid hormone generally potentiates the 
action of ~pinephrine on o:xygen cons~unption and basal metabolic rate 
(Lardy, 1957), and heart rate (Sawyer and Brmm, 1935; Hoffmann ~ al., 
1957; Gravenstein and Thier, 1960). The potentiation of epinephrine's 
activity on the resting blood pressure (Gerlei, 1938; Spinks, 1952) of 
rabbits and on isolated swine arteries (Srqith, 1954) and rabbit duodenum 
(Trendelenburg, 1953) has been interpreted in terms of a decrease in tissue 
monoamine oxidase (MAO) levels or a reduction in the enzyme's activity 
engendered by thyroid hormone. 
Similarly, Burn and Marks (1925) have found that feeding thyroid to rabbits 
increases their sensitivity to epinephrine-induced hyperglycemia. This 
hormonal "priming" effect was later ascribed to the ability of thyroid 
hormone to diminish hepatic MAO activity (Spinks and Burn, 1952; 
Trendelenburg, 1953). Although there have been some reports to the con-
trary (Westermann, 1956; Holtz et al., 1956), this in vivo inhibitory 
action of thyroid hormone on hepatic MAO in rodents seems reasonably 
well-established by the work of Zile and Lardy (1959, 1960), Calvert and 
Brody (1961), and Novick (1961). The hypothesis of Zile and Lardy (1959) 
that thyroid hormone regulates the biosynthesis of hepatic MAO has been 
supported by others (Ozaki et al., 1960). 
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Further, whether the action of thyroid hormone is primarily upon MAO, 
0-methyltransferase, or both, the fact remains that the administration 
of thyroid elevates catecholamine blood levels and increases their urinary 
excretion in animals (Zile and Lardy, 1959; D'Iorio and Leduc, 1960) and 
man (Diwani et al., 1960). 
Bailey et al. (1959), KJ.ine (1961), and Saunders (1962) have found that 
melancholic patients medicated for several d.a;ys with both thyroid and 
iproniazid, an irreversible MAO inhibitor and antidepressant, paradoxically 
became apathetic a.nd sluggish, ashen and cyanotic in appearance, and 
showed evidence of a fall in blood pressure. These adverse behavioral and 
gross physical or somatic effects necessitated withdrawal of the antide-
pressive agent. 
In light of these seemingly peculiar and contradictory effects, the present 
investigation was designed in preliminary fashion to determine what action 
thyroid feeding had, if a:rry, on the pharmacodynam.ic actions of irreversible 
acting MAO inhibitors, and to attempt to explain, at least on a gross 
somatic basis, the reason for the reported psychotherapeutic incompati-
bility between concurrent thyroid and MAO inhibitor medication. 
MATERIAI.S AND Mm'HODS 
An:imals .-
Sixty male albino Wistar rats, ranging in weight trom 170-210 gm., were 
randomly divi~d into 10 groups of 6 animals each. All groups were caged 
separately and the environmental temperature was kept between 25-27° C 
throughout the study. 
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Drugs and Dosage Protocol.~ 
Iproniazid (l-isonicotinyl-2-isopropylhydrazine) phosphate (Ma.rsilid(l)) 
and pargyline (N-benzyl-N-methyl-2-propynyla.mine hydrochloride; ~10-911; 
Eutony1(2)) were used as irreversible MAO inhibitors. Both drugs were 
freshly prepared by dissolving the respective salts in physiological saline 
solution. Injections were given intraperitoneally. Starting on the eighth 
day of drug diet feeding, animal groups I and VII received 250 mg/Kg of 
iproniazid phosphate, and groups II and VIII received 175 mg/Kg daily. 
Groups III and IX received 25 mg/Kg of pargyline hydrochloride, a.11d IV and 
X received 10 mg/Kg daily. These latter doses were selected because pargy-
line in vitro is almost 8 times (Taylor et al., 1960) and in vivo (intra-
peri toneally) about 12 times more potent an irreversible MAO inhibitor in 
the rodent than iproniazid (Everett, 1962). 
The remaining two groups (V f¥1d VI) were not medicated with the synthetic 
enzyme inhibitors. 
Diet ~Feeding Protocol.~ 
Control group v, which received neither an MAO inhibitor nor thyroid sub-
stance, was given Purina Lab Chow (Ralston Purina Co.) ~ libitum in a 
special retabletted form. A 2 % thyroid drug diet was prepared by homo-
geneously combining desiccated thyroid U.S.P., with the powdered lab chow 
(l)Registered trademark of Hoff'mann-La Roche, Inc., U.S.A. 
(2 )Registered trademark of Abbott Laboratories, U.S.A. 
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and retabletting the granulation using suitable excipients. Incorporation 
of thyroid substance into the diet of the rats was felt most suitable in 
that it 'WOuld allow gradual medication and continuous absorption to take 
place. 
Initially, all 60 rats were fed the control diet for 7 days. On day 8, 
groups I through V were continued on this diet while groups VI through 
X were fed the thyroid ration. Consequently, groups VII and VIII receiving 
iproniazid also received 2 'to thyroid, while t;roups IX and X were fed the 
thyroid diet and received daily injections of pargyline. All animals were 
maintained on their respective diets for an additional 21 days or, where 
fatalities occurred, until the entire group died. To prevent or retard 
vitamin A deficit and weight loss normally evoked by hyperthyroidism, as 
well as for purposes of dietary standardization, all an:i.ma.ls were given 
orally 3 drops of Oleum Percomorph1..U11 (Mead Johnson) every third day. The 
animals had free access to water at all times. 
Histopathologic Studies.--
Immediately after death or sacrifice, samples of liver, kidney, and spleen 
were removed from one or more representative animals of groups II, III, 
IV, and v. The tissues were fixed in Bouin's solution and, a~er pre-
paration and section (10 microns), were stained with hemato.xylin and 
eosin and examined for general morphologic chru1ges. 
Blood Pressure Studies.--
Indirect systolic blood pressures of each animal were taken daily usinG 
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a precalibrated photoelectric tensometer; the technique of Kersten et al., 
(1947) was followed. Fright and other like interfering stresses were 
avoided by training a.11 animals to accommodate the pressure cuff before 
beginning the drug studies. Direct instrument values were read in mm Hg; 
in no case were they read greater than the closest 5 mm Hg. When fatalities 
due to drug treatment occurred, readings were taken for not less than 3 
surviving animals of the particular group. The normal, mean systolic 
blood pressure and standard deviation of the entire 60 rats -was calculated. 
Confidence intervals were calculated according to standard statistical 
procedures (Ostle, 1954) for the true mean pressure of such untreated 
animals. 
Urinary Dopamine Studies.~ 
Twenty-four hour urine sa.~ples from groups II, v, and VI were collected 
in 2N sul:furic acid on the eighth and fi~eenth ~s of drug administration. 
The pooled samples were filtered and processed for the extraction of 
catecholamines (Crawford and Law, 1958). An aliquot was passed through 
a strongly acidic, cationic exchange resin (Dowex 50W, X-8, Na+ form) 
column, and the dopamine was eluted from the resin by 8 ml of 2N hydro-
chloric acid (Bertler et al., 1958). Dopamine concentrations were determined 
by using the trihydro~indole-fluorimetric method of Carlsson and Waldeck 
(1958) and an Aminco-Bo'WIIlal1. spectrophotofluorometer (American Instrument 
Co.). 
Fasting Blood Glucose Determinations.~ 
Blood samples were obtained every third day by direct intracardiac puncture 
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and were made, immediately following blood pressure recordings, from 
lightly anesthetized (pentobarbital sodium, 20 mg/Kg i.p.) rats. All animals 
were fasted for 17 hours prior t~ the blood sampling. Blood glucose concen-
trations for each animal were determined color:Unetrically (Nelson, 1944; 
Somogyi, 1945) using a precalibrated Spectronic 20 color:Uneter (Bausch and 
Lomb) and 12.7 mm diameter cuvettes. Individual concentrations were read 
as optional density units, and these were transfonned into mg/l(X) ml by 
referring to a calibration curve. The individual values were averaged to 
obtain group means, and standard deviations were calculated. Confidence 
intervals, as before, were calculated for the true, untreated, rat mean 
blood glucose concentration. 
RESULTS 
General Observations.~ 
The MAO inhibitor-treated animals exhibited a somewhat diminished random 
motor activity and were easier to handle than unmedicated controls. Within 
3-4 days, all thyroid-fed rats became considerably irritable, but in those 
groups 'Where both enzyme inhibitor and thyroid were administered the hyper-
excitability vas less apparent. In fact, the sluggishness and asthenia of 
these dually medicated animals became increasingly pronounced as the drug 
treatments continued. 
Food and water consumption was generally decreased in the MAO inhibitor-
treated groups, but this effect was less pronounced with the pargyline 
treatments • Thyroid-fed animals ate and drank avidly, 'While hyperthyroid 
rats given either of the enzyme inhibitors seemed restrained in their 
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feeding habits. Death of the MAO inhibitor-treated animal.s was always 
preceded by complete inanition. Mean body weights of euthyroid rats 
under iproniazid medication fell steadily especially during the first 9 
da\Y's of injection, while the body weights of similar animals under pargyline 
showed either slight decreases or moderate increases. A relatively slow, 
but progressive weight decline also occurred in the thyroid-fed rats a~er 
an initial 5-day increase. Untreated animals maintained on the control 
diet showed nonnal weight gains, and at the end of 3 weeks weighed, on the 
average, 45 gm more than the hyperthyroid control animals. A sporadic 
incidence of diarrhea was common in all enzyme inhibitor-treated rats; 
it was particularly evident in thyroid-fed animals. The feces of MAO 
inhibitor-treated rats were coated with considerable intestinal mucus. 
Considerable blood was noted in urine samples from iproniazid-treated rats; 
blood specimens contained laked erythrocytes. Iproniazid-medica.ted rats 
regularly showed reddish-colored ocular discharges that resembled dried 
blood; this effect was less frequently observed with pargyline. An ab-
normal degree of salivation occurred with both iproniazid and pargyline 
treatments in euthyroid and hyperthyroid animals, but this effect appeared 
more prevalent with the nonhydrazine compound. 
Subacute Toxicity.~ 
Symptoms of iproniazid toxicity rapidly developed. In group I, given 
250 mg/Kg of iproniazid daily, a few rats died on the second da\Y of in-
jection; all animals of this group died within 8 ~s (Table I). 
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[Table I Here) 
'l'he lower dose of iproniazid (175 mg/Kg) was considerably less toxic. 'l'he 
feeding of 2 % desiccated thyroid concurrently with injected iproniazid at 
both dose levels (groups VII and VIII), however, hastened their deaths 
3- to 4-fold. Although the feeding of thyroid alone (group VI) or the 
administration of pargyline at 10 (group IV) and 25 mg/Kg (group III) 
alone caused no fatalities, the concurrent administration of both thyroid 
and MAO inhibitor (groups IX and X) resulted in the deaths of all animals 
within 15 deys. 
Histopa.thologic Studies.~ 
Livers removed from rats 'Which had received iproniazid for 21 deys showed 
small superficial lesions. The kidneys of these animals appeared abnormally 
dark red in color; spleens, on the other hand, were almost black. Histo-
logic examination of these organs revealed hepatocellular damage, renal 
tubule necrosis, and considerable erythrocyte fragmentation in the spleen. 
Rats sacrificed after 21 de\Ys of pargyline dosing exhibited none of these 
tissue changes; several of the spleens in these groups, however, appeared 
abnormally dark red in color. Tissues from thyroid-MAO inhibitor-treated 
animals were not examined. 
Table I 
SUbacute Toxicity in Rats of Desiccated Thyroid, Iproniazid, 
and Pargyline, Alone and in Combination 
Group 
Daily Intraperitoneal Dose 
of MAO Inhibitor (mg/Kg) Diet Deaths 
I Iproniazid ro4 Control All within 8 days 250 
II Iproniazid ro4 Control 2 within 21 days 175 
III Pargyline HCl Control None 
25 
IV Pargyline HCl control None 
10 
v None Control None 
VI None 2 % Thyroid None 
VII Iproniazid P(\ 2 'fa Thyroid All within 2 days 
250 
VIII Iproniazid ro4 2 'fo Thyroid All within 6 days 175 
IX Pargyline HCl 2 % Thyroid All within 14 deys 
25 
x Pargyline HCl 2 % Thyroid All within 15 days 
10 
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Blood Pressure and Urinary Do;pamine Studies.~ 
The normal, mean systolic blood pressure and standard deviation (S .D.) 
of the 60 rats were calculated to be 110.::, 7.66 mm Hg. Confidence limits 
(99 i) of 107.4-112.6 mm Hg were calculated for the true mean in the un-
treated rats. 
It can be seen from Figures 1-l+ that a slight time factor exists in the 
response to drug or thyroid treatments. Moreover, most animals in the MAO 
inhibitor groups did not show synchronous changes in blood pressure so that 
the intragroup variability, for any given day, was. generally more marked 
than that observed in control ~r pretreatment periods. Therefore, the 
following very conservative statistical procedure and reasoning was adopted: 
the S.D. of the mean of a sample of 6 animals, drawn from the same popu-
lation as the 60 control observations, -would be the S.D. of the general 
:population divided by the square root of 6, i.e., .2.4495. Any mean of a 
sample of size 6 that differed from the :population mean by more than 2.58 
times the S.D. divided by 2.4495 -would be significantly different at the 
1 i level. When, as in the pr~sent situation, the true S.D. is not knoYin, 
the estimated value (7 .66 mm Hg) may be used if the normal distribution 
critical value of 2. 58 is replace"d by the critical value of Student's "t" 
with the appropriate number of degrees of freedom, i.e., d.f. = 59; 
"t" = 2.660. Thus, making the conservative assumption that the true mean 
is as likely to be at the upper boundary of the conf'idence interval as at 
its center, a;ny mean of a sample of 6 that lies outside the calculated con-
fidence interval by more than 2.66o times the S.D. divided by 2.4495 is 
significantly different from the true mean of the control :population, 
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at the 1 ~ level, if indeed the confidence interval does contain the true 
mean. Since we have 99 <{o confidence that it does contain the mean, we can 
Sf3¥ with not less than 98.0l % confidence that a:ny such outlying small 
sample (6) mean comes from a population other than that of the untreated 
rats, and is, therefore, a true difference. Applying these calculations, 
98 tfo "critical limits" were determined for the control mean blood pressure 
and are represented by the continuous, horizontal lines in Figures 1-4. 
The 24-hour pooled urinary dopamine concentrations of the nonmedicated 
controls (group V) _were estimated on df3¥s 8 and 15; these quantities were 
found to be 362 and 475 pg/l of urine respectively. In our laboratory, 
these amounts are considered representative. The mean arterial blood 
pressures taken on these same fucy"s were 110 + 8.5 and 112 :t 7.9 mm Hg 
respectively. 
As shown in Figure 1, iproniazid at the 175 mg/Kg daily dose level (group 
II) unifo~ caused statistically significant presser effects a.f'ter fucy" 1. 
(Figure 1 Here] 
Blood pressures continued to rise until df3¥ 5 when they plateaued. On 
~ 9 and 10, the systolic pressures fell precipitously and, except for 
a rise on df3¥ 11 of treatment, became rather erratic and remained only 
barely above or within normotensi ve levels for the remainder of the treat-
ment period. The urinary dopamine le·ve1 for this same group was almost 
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twice the normal on day 8. On day 15, were the mean blood pressure, sur-
prisingly enough, was almost normal (116 ~ 27.0 mm Hg), the excretion was 
approximately 5 times greater than customary. 
The blood pressure effects of pargyline at the 25 mg/Kg daily dose level 
are shown in Figure 2. 
[Figure 2 Here] 
In contrast with iproniazid, pargyline produced an initial, transient 
hypotensive effect that reached a maximum on day 3. After day 6, mean 
pressures rose for 3 days and attained a mean peak of about 155 mm Hg on 
day 9. Pressures fell on day 10, but they stabilized slightly above 
normotensive levels thereafter. At the lower dose (10 mg/Kg daily, group 
IV), pargyline elicited somewhat similar blood pressure effects, but the 
mean, peak presser effect (163 mm Hg) did not occur until day 13. On 
days 16 and 17, mean pressures fell to about 127 mm Hg, Vlhereupon a 
presser effect (up to 145 mm Hg) again supervened on day 18 that per-
siste~ until the end of the treatment period. 
The feeding of desiccated thyroid caused a definite, gradually developing 
presser effect first noted on day hj peak pressures of about 160 mr:i. Hg 
occurred on da\)" 16 (Figure 3). 
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[Figure 3 Here] 
Individual blood pressures in this group were much less variable than in 
a:ny of the MA.O inhibitor-treated animals. There was no evidence of a 
return to normotensive levels while thyroid feeding was continued. 
Irrespective of the pressor responses, pooled dopenine excretion values on 
days 8 and 15 were 482 and 517 pg/l of urine respectively. These values 
for the thyroid-fed group were not considered abnormally high. 
The feeding of 2 % thyroid to iproniazid-medicated animals (groups VII and 
VIII) decimated the respective groups in such rapid fashion (Table I) 
that the recording of the erratic blood pressures and blood glucose concen-
trations was made almost impossible and gave little basis for interpretation. 
Figure 4 shows the blood pressure effects in rats treated with 25 mg/Kg of 
pa.rgyline and 2 ~ thyroid. 
[Figure 4 Here] 
It is obvious that although the variation in blood pressures among the 
individual animals of the group was large, a definite presser effect began 
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after the second da.y a.nd, except for a fall on day 9, was maintained until 
day J2 when the blood pressures of the surviving animals of the group fell 
sharply thereafter to nonnotensive or slightly hypotensive levels. No 
evidence of any initial transient fall in blood pressure as in the pargyline-
treated rats was detected. 
The collateral treatment of rats with 10 mg/Kg of pargyline and 2 % thyroid 
gave effects roughly equivalent to the higher dose of pa.rgyline and thyroid 
feeding. The peak mean pressure occurred on da.y 6 and thereafter fell 
slowly, but erratically, to a minimum of 88 mm Hg on day 12. The blood 
pressures stabilized at about 105 rrun Hg therea~er. The entire group died 
between deys 14 and 15. 
Fasting Blood Glucose Studies.~ 
The blood glucose mean and standard deviation of the 60 control measure-
ments were calculated to be 104 :!: 11.20 mm °fo. Confidence limits (99 ~) 
of 107.9-100.1 mg% were calcul.ated for the true mean in the untreated 
rats. Employing the same statistical reasoning as adopted for the blood 
pressure studies, the 98 % "critical limits" were determined for the 
control mean and a.re represented by the broken, horizontal lines in Figures 
1-4. 
AB readily evident from the figures, 3-week daily treatment with either 
one of the enzyme inhibitors and/or desiccated thyroid generally failed 
to statistically mod.i:f'y mean blood glucose concentrations although fluctu-
ations did occur; only in those animals near death from MAO inhibitor 
treatment did the concentrations fall. 
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DISCUSSION 
Although not quantitated, both hydrazide and nonhydrazide f>'IAO inhibitors 
in the doses employed did not elicit any gross evidence of hyperexcitability 
or an increase in general random motor activity. Certainly one explanation 
for the generalized depression of activity may be simply a reflection of 
subacute toxicity. The hyperirritability of the hyperthyroid rats, as 
well described by a number of other workers (French, 1912; Watanabe and 
Nomura, 1937), was completely reversed in those animals receiving both 
thyroid and an Ml\O inhibitor. The somato-motor weakness and sluggishness 
of these animals most likely is a reflection of general apathy and a..~ 
index of an accelerated toxicity in animals whose general metabolisn has 
already been seriously disturbed. 
The general increase in food and water intake of the thyroid-fed rats, 
irrespective of their hampered weight gains, agrees with the reports of 
Carlson~~· (1912), French (1912), and Barker (1951); these effects 
are undoubtedly accounted for by an increased metabolic rate and the con-
stant need to satisfy such a demand. No doubt the collateral use of 
vitamins A and D offset, to an extent, some of the adverse effects of 
high doses of thyroid. The exaggerated weight decline in the animals 
dosed with both hormone and an MAO inhibitor is most likely a nonspecific 
symptom of drug-induced toxicity. 
The diarrhea noted in almost all thyroid-fed rats is a commonly observed 
untoward effect (gastrointestinal hypermotility) in thyroid-sensitive 
animals (Carlson et al., 1912; French, 1912). The marked diarrhea in 
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the MAO inhibitor-treated rats is difficult, however, to reconcile with 
the frequently reported constipating effect of iproniazid in man (O'Connor 
et al., 1953; Alexander and Berkeley, 1959; Weiss et al., 1959). The 
elimination of fecal matter coated with mucus was also a common finding 
in the iproniazid- and pargyline-medicated rats. Hypermucosity has been 
reported with the clinical use of other ~..AO inhibitor antidepressants 
(Sainz, 1959); this side effect in both man and rat may possibly indicate 
incipient gastroenteritis. 
Hematuria and the presence of laked erythrocytes were commonly found in 
blood samples from iproniazid - but not pargyline-treated rats. The 
hemolytic effects of hydrazine and its analogues are -well-documented, 
and the above toxicity -we observed may be related to the hydrazine moiety 
of iproniazid. Hemolytic anemia has only rarely been reported to occur 
in man ( 0 'Connor et al., 1953) with iproniazid use. Moreover, histo-
pathologic studies in other rodents medicated with relatively high doses 
of hydrazides have shown signs of increased erythrocyte destruction, as 
evidenced by hemosiderosis of the kidney, liver, and spleen, and hyper-
emia or darkening of the latter organ (Benson et al., 1952; Zbinden and 
Studer, 1959) . These reports, the hemolys is noted in our stuay, and the 
reported hepatic and splenic accumulation of iproniazid a~er parenteral 
administration (Koechlin and Iliev, 1959) may explain the organ darkening 
and injury observed by us. The lack of gross hemolytic changes with 
pargyline contributes presumptively to the impression that such toxicity 
is most probably due to the hydrazine moiety of iproniazid. A rather 
singular toxic effect was the reddish ocular discharges (chromodacryorrhea-
like) that occurred with subacute administration of both iproniazid and 
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pa.rgyline. The only comparable effect, knO"Wil to us, is the report of an 
ocular discharge of a. porphyrin-like material in rats given subacute doses 
of etrypta.mine acetate, a. new indole MAO inhibitor {Gr~, 1961). 
The rapid onset of ipronia.zid toxicity was not particularly surprising 
as the intra.peritoneal doses used -were very high. What "Was unexpected, 
however, were the rapidity and high incidence of fatalities in the simul-
taneously enzyme inhibitor- and thyroid-medicated rats. The administration 
of desiccated thyroid or thyroxine is knovin to modif'y the susceptibility 
of animals to the toxic effects of a number of drugs. Although large 
doses of thyroid !lla\Y.produce liver damage (Barker, 1951), the rapid onset 
of toxicity and high incidence of fatality in those animals receiving 
either one of the synthetic MAO inhibitors and thyroid seems to imply that 
the metabolic effects of the latter accentuate the direct, subacute toxicity 
of large doses of the antidepressants. This assumption is :f'Urther strengthened 
by our previous findings that hyperthyroidism increases the a.cute toxicity 
of pe.rgyline in rats (Carrier and Buday, 1961) . Whether these toxic effects, 
acute or subacute, are in a;ny way related to a. combination of the in vivo 
MAO inhibitory effects of thyroid hormone and the synthetic enzyme in-
hibitors with a. resultant elevation of catecholamines {Leduc ~ al., 
1955; Zile and Lardy, 1959) or serotonin (Put and Hogenhuis, 1962), no 
conclusion can be dra."W?l at this time; further work {behavioral and enzymatic), 
however, is in progress to study these possible causal relationships. In 
a;ny event, the stress of impending thyrotoxicosis in the MAO inhibitor-
trea.ted animals in our study may, in some superficial fashion, parallel 
the clinical reports of a pharmacothera.peutic incompatibility during 
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simultaneous medication with thyroid extract and irreversible MAO inhibitors 
(Bailey et al., 1959; Kline, 1961). 
--
The blood pressure responses to prolonged administration of both iproniazid 
and pargyline showed la,rge variations and wcy- be explained on the basis of 
oscillating responses and the small sample size. Because of the great 
dose difference between iproniazid and pargyline, little comparative 
importance can be given to the latter drug's minor primary bypotensive 
effects • What is perhaps of some importance is the fact that a pressor 
effect induced by repeated dosing with both drugs did occur. flY:pOtension 
is a common side effect during protracted medication with .the MAO inhibitors 
and when given acutely to animals in relatively low doses (Cahn and Herold, 
1962). Single, massive parenteral doses of iproniazid, however, cause a 
rise in rabbit blood pressure (De Palol and Lemberg, 1962). Dopamine, the 
biogenic precursor of norepinephrine and epinephrine, is a weak pressor 
material in the rat (Vogt, 1959). Its metabolism is reduced or blocked 
by MAO inhibitors (Horwitz~ al., 1962), and we speculated that the 
pressor effects persisting from the second to eighth day with iproniazid 
dosing might be correlated vith the urinary excr~tion of the catecholamine. 
No such correlation was able to be made, however. Dopamine excretion 
values were elevated approximately 100 ~ on day 8 'When the mean systolic 
blood pressure was some 55 mm Hg above the normal, but on day 15, 'When 
dopamine excretion values were increased about 400 %, the mean blood pressure 
was within normal. limits. 
Hypertension is a frequent concomitant of clinical hyperthyroidism (Logan, 
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1930). In rats, thyroxine-induced hypertension was explained by Samiy (1952) 
as due to an altered receptor sensitivity to dopainine. Dopamine excretion 
"W8.S not significantly elevated in our thyroid-fed rats, however, and hence 
the presser effects in the hyperthyroid rats may have no relationship to 
this catecholamine. Furthermore, hyperthyroidism inhibits hepatic dopa 
decarbo.xylase, the enzyme responsible for the rapid conversion of 3,4-
dihydro.xyphenylalanine (dopa) to dopamine (Clark, 1959). Considering this, 
and the avidity of MAO for dopamine, it is tempting to speculate about 
these mutua.l.ly antagonistic properties of thyroid hormone on those enzymes 
plEcy'ing a significant role in the biotransformation of dopamine and the 
reason for the normal dopamine excretion values in hyperthyroid rats. 
Whereas the daily injection of pargyline alone uniformly elicited a slight, 
primary depressor response la.sting as long as the fourth da¥ of medication, 
the administration of pargyline to thyroid-fed rats obliterated this 
initial effect; a presser effect was evoked a.s early as dEcy' 3 and although 
temporary, the presser effects were somewhat greater than that with either 
hormone or drug given alone. The sudden and precipitous fall in blood 
pressure occurring on da¥s 11 and 12 in those groups (IX and X) receiving 
both pargyline and thyroid cannot be readily explained. Certain.4" cardio-
vascular collapse, a prelude to death, is a possibility. 
Parenteral administration of hydrazine sulfate in large doses elicits hypo-
glycemia in animals (Underhill, 1911), and clinical reports of diminished 
blood glucose levels during iproniazid therapy have been published (Weiss 
~ al • , 1959; Aksel, 1960) • Contrary to expectations, however, no statistically 
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significant blood glucose changes occurred with iproniazid; no significant 
changes occurred with pargyline. Similarly, thyroid feeding elicited no 
blood glucose changes in rats; ordinarily the feeding of large quantities 
of thyroid to dogs and rats (Houssay, 1944) or hyperthyroidism in man 
(Geyelin, 1915) results in a definite hyperglycemia. The reason for our 
inability to duplicate these effects in our study is obscure. 
SUMMARY 
Daily intraperitoneal injections of massive doses of iproniazid phosphate 
and high doses of pargyline hydrochloride for as long as three weeks markedly 
reduced the general motor activity and body weight of male rats. Both of 
these effects, the general malaise, and the incidence of mortality was 
increased by the daily feeding of a high concentration of desiccated thyroid. 
Limited gross and microscopic studies showed that iproniazid (175 mg/Kg 
daily) caused hepatic, splenic, and renal injury, and hemolysis. Pargyline 
(10 and 25 mg/Kg daily), other than causing splenic darkening, showed no 
comparable effects. 
Although exhibiting large fluctuations, systolic blood pressures rose 
rapidly, but only temporarily, in iproniazid-treated rats. Significant 
presser effects in pargyline-dosed rats began only after 7 days. The 
collateral feeding of thyroid to pargyline-treated animals accelerated the 
. 
onset and accentuated the presser effects. The feeding of thyroid alone 
elicited a slowly developing and uniform presser effect. Limited dopamine 
studies in normal, iproniazid- and thyroid-medicated rats showed that there 
was no apparent correlation between the presser responses and the excretion 
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of dopamine. No significant changes in fasting blood glucose concentrations 
occurred during subacute administration of the MAO inhibitors or thyroid 
alone, nor when the treatments were concurrent. 
-21-
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A method found sim~le and expeditious to produce an acceptable 
remade~chow tablet, using limited and easily accessible equipment, was 
to crush the hard, brittle pellets by use of a Wiley laboratory mill, passing 
the coarse material thence through a Mikro Samplmill (model 579A) to 
give a number 60 powder or finer. To ea~h 100 g of this powder was 
added 40 ml of a warm, freshly prepared, gelatin-acacia solution made by 
dissolving 10 g of Gelatin (granular) U.S. P. and 1 g of Acacia (powder) 
U.S. P. in 100 ml of boiling distilled water. The binder and powders 
were then mixed thoroughly to form a d0amp mass. The latter was then 
sifted through a number 10 mesh brass ·screen to form granules. These 
particles were then passed through a number 20 mesh screen to obtain 
a finely granulated mass. 
Using a hand driven, single punch, Stokes tablet machine (model 
A-3 Eureka) with a 1. 27 cm standard concave punch and die set for 
maximum fill (1. 09 cm), the damp granulation was compressed into 
O. S g convex tablets having 2. 0 mm edge thickness. The pressure on the 
punch approximated 7. S tons per 1square inch. The tablets were allowed 
to dry and harden thoroughly at ambient room temperature (approximately 
21°c) for 36 hours or longer. 
